Inhibition of mesenchymal stromal cells by pre-activated lymphocytes and their culture media

Stem Cell Research and Therapy

Volumn 5, Issue 1, 2014, Pages

  Valencic, Erica ^a   Loganes, Claudia ^a   Cesana, Stefania ^b,c   Piscianz, Elisa ^a   Gaipa, Giuseppe ^b,c   Biagi, Ettore ^b,c   Tommasini, Alberto ^a  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; CULTURE MEDIUM; CYTOKINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL GROWTH; CELL INTERACTION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMA CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PHARMACOLOGY; PHYSIOLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; CYTOKINES; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS;

EID: 84892150922     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt392     Document Type: Article

References (26)

1. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Friedenstein AJ, Chailakhjan RK, Lalykina KS, Cell Tissue Kinet 1970 3 393 403 5523063
2. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, Stem Cells 2004 22 1330 1337 10.1634/stemcells.2004-0013 15579650 (Pubitemid 39636408)
3. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Meyers P, Chiarieri D, McKenzie S, Broxmeyer HE, Moore MA, Blood 1980 56 289 301 6994839 (Pubitemid 10043431)
4. Mesenchymal stem cells. Caplan AI, J Orthop Res 1991 9 641 650 10.1002/jor.1100090504 1870029
5. Multilineage cells from human adipose tissue: implications for cell-based therapies. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH, Tissue Eng 2001 7 211 228 10.1089/107632701300062859 11304456 (Pubitemid 32295155)
6. Muscle-derived stem cells. Jankowski RJ, Deasy BM, Huard J, Gene Ther 2002 9 642 647 10.1038/sj.gt.3301719 12032710 (Pubitemid 34575318)
7. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E, Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606 (Pubitemid 44269669)
8. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O, Lancet 2008 371 1579 1586 10.1016/S0140-6736(08)60690-X 18468541 (Pubitemid 351626841)
9. Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study. Arima N, Nakamura F, Fukunaga A, Hirata H, Machida H, Kouno S, Ohgushi H, Cytotherapy 2010 12 265 268 10.3109/14653240903390795 19961282
10. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J, Biol Blood Marrow Transplant 2009 15 804 811 10.1016/j.bbmt.2008.03.012 19539211
11. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, Salvadè A, Capelli C, Belotti D, Gaipa G, Perseghin P, Vinci P, Lanino E, Chiusolo P, Orofino MG, Marktel S, Golay J, Rambaldi A, Biondi A, D'Amico G, Biagi E, Biol Blood Marrow Transplant 2010 16 1293 1301 10.1016/j.bbmt.2010.03. 017 20350611
12. Human multipotent adult progenitor cells are non-immunogenic and exert potent immunomodulatory effects on alloreactive T cell responses. Jacobs SA, Pinxteren J, Roobrouck VD, Luyckx A, Van't Hof W, Deans R, Verfaillie CM, Waer M, Billiau AD, Van Gool SW, Cell Transplant 2012 22 1915 1928 23031260
13. Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies. Hoogduijn MJ, Roemeling-van Rhijn M, Korevaar SS, Engela AU, Weimar W, Baan CC, Hum Gene Ther 2011 22 1587 1591 10.1089/hum.2011.039 21732766
14. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Morandi F, Raffaghello L, Bianchi G, Meloni F, Salis A, Millo E, Ferrone S, Barnaba V, Pistoia V, Stem Cells 2008 26 1275 1287 10.1634/stemcells.2007-0878 18292209
15. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L, Blood 2006 107 1484 1490 10.1182/blood-2005-07-2775 16239427 (Pubitemid 43242385)
16. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L, Blood 2008 111 1327 1333 17951526 (Pubitemid 351213419)
17. The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation. Valencic E, Piscianz E, Andolina M, Ventura A, Tommasini A, Cytotherapy 2010 12 154 160 10.3109/14653240903493417 20078387
18. Monitoring human mesenchymal stromal cell differentiation by electrochemical impedance sensing. Angstmann M, Brinkmann I, Bieback K, Breitkreutz D, Maercker C, Cytotherapy 2011 13 1074 1089 10.3109/14653249.2011. 584863 21619493
19. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Bryceson YT, Pende D, Maul-Pavicic A, Gilmour KC, Ufheil H, Vraetz T, Chiang SC, Marcenaro S, Meazza R, Bondzio I, Walshe D, Janka G, Lehmberg K, Beutel K, zur Stadt U, Binder N, Arico M, Moretta L, Henter JI, Ehl S, Blood 2012 119 2754 2763 10.1182/blood-2011-08-374199 22294731
20. Macrophages modulate the viability and growth of human mesenchymal stem cells. Freytes DO, Kang JW, Marcos I, Vunjak-Novakovic G, J Cell Biochem 2012 114 220 229
21. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Liu Y, Wang L, Kikuiri T, Akiyama K, Chen C, Xu X, Yang R, Chen W, Wang S, Shi S, Nat Med 2011 17 1594 1601 10.1038/nm.2542 22101767
22. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B, Lataillade JJ, Bourin P, Holy X, Vernant JP, Klatzmann D, Cohen JL, J Immunol 2006 176 7761 7767 16751424 (Pubitemid 43849077)
23. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Renner P, Eggenhofer E, Rosenauer A, Popp FC, Steinmann JF, Slowik P, Geissler EK, Piso P, Schlitt HJ, Dahlke MH, Transpl Proc 2009 41 2607 2611 10.1016/j.transproceed.2009.06.119
24. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Chang CJ, Yen ML, Chen YC, Chien CC, Huang HI, Bai CH, Yen BL, Stem Cells 2006 24 2466 2477 10.1634/stemcells.2006-0071 17071860 (Pubitemid 44674307)
25. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Ryan JM, Barry F, Murphy JM, Mahon BP, Clin Exp Immunol 2007 149 353 363 10.1111/j.1365-2249.2007.03422.x 17521318 (Pubitemid 47063057)
26. Interplay between mesenchymal stem cells and lymphocytes: implications for immunotherapy and tissue regeneration. Wang L, Zhao Y, Shi S, J Dent Res 2012 91 1003 1010 10.1177/0022034512460404 22988011